Breaking News

Everest Medicines Begins Ops at mRNA Vaccine Production Site in China

Site in Jiashan, Zhejiang Province is designed with an annual production capacity of 700 million doses of mRNA vaccines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, began the first phase of operations at its global manufacturing site dedicated to mRNA vaccine production in Jiashan, Zhejiang Province.   The first phase of the project, covering an area of 58,000 square meters and with an investment of more than RMB 900 million, has a set of advanced production facilities built to meet global and China GMP stand...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters